PT - JOURNAL ARTICLE AU - Rauber, Conrad AU - Tiwari-Heckler, Shilpa AU - Pfeiffenberger, Jan AU - Mehrabi, Arianeb AU - Lund, Frederike AU - Gath, Philip AU - Mieth, Markus AU - Merle, Uta AU - Rupp, Christian TI - SARS-CoV-2 seroprevalence and clinical features of COVID-19 in a German liver transplant recipient cohort: a prospective serosurvey study AID - 10.1101/2020.09.30.20204537 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.30.20204537 4099 - http://medrxiv.org/content/early/2020/10/04/2020.09.30.20204537.short 4100 - http://medrxiv.org/content/early/2020/10/04/2020.09.30.20204537.full AB - In liver transplant (LT) recipients with severe COVID-19 fatal outcome has been reported in a substantial subset of patients. Whether LT recipients are at increased risk for severe COVID-19 compared to the general population is controversial. Here we report the first results of a SARS-CoV-2 serosurvey in a large LT recipient cohort.Taking into account known risk factors, LT recipients a priori represented a high-risk cohort for severe COVID-19 with 101/219 (46.1 %) presenting with more than 2 risk factors for severe COVID-19. Out of 219 LT recipients 8 (3.7%) were either tested positive for nasopharyngeal SARS-CoV-2 RNA or anti-SARS-CoV-2 serum IgG. 5/8 (62.5 %) did not show any clinical signs of infection, 3/8 (37.5%) had self-limited disease, none required hospitalization for COVID-19. 5/8 (67.5%) SARS-CoV-2 positive patients showed high utilization of the healthcare system. 2/8 (25 %) had known exposure to infected health care personal. A majority of 65.4 % often or always avoided outside family social contacts. Face masks were commonly worn by all patients.In summary, LT recipients showed a SARS-CoV-2 seroconversion rate similar to the general population with a substantial percentage of unrecognized infections. The health care system can be the assumed source of infection in most of these cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the University Hospital Heidelberg, Department Gastroenterology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Medical Faculty of the University of Heidelberg (approval number S-457/2020). The study was conducted in accordance with good clinical practice (GCP) and the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request. contact conrad.rauber@gmx.deCOVID-19coronavirus disease 2019CRPC-reactive proteinLTliver transplantationPCRpolymerase chain reactionSOTsolid organ transplantationSARS-CoV-2Severe acute respiratory syndrome coronavirus 2